X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Menarini will acquire rights to commercialize, upon approval, VNRX-5022/VNRX-5133 (cefepime-taniborbactam), an investigational IV beta-lactam/beta-lactamase inhibitor antibiotic combination for complicated urinary tract infections, in 96 countries.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: VNRX-5022
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: VenatoRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 09, 2024
Details:
Under the agreement, Stemline will have the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Insilico Medicine
Deal Size: $512.0 million Upfront Cash: $12.0 million
Deal Type: Licensing Agreement January 04, 2024
Details:
Under the agreement, SciClone will pursue the development and registration of Orserdu (elacestrant), a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, in China and commercialize Orserdu upon its regulatory approval in China.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciClone Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 07, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Organisation for Research and Treatment of Cancer
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
The company has signed an agreement to acquire five legacy brands are Piclin, Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor) catering to gastroenterology, urology and anti-infective segments.
Lead Product(s): Sodium Picosulfate
Therapeutic Area: Gastroenterology Product Name: Piclin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: $12.1 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 22, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
MEN1703 (SEL24) is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile, which is investigated for the treatment of diffuse large B-cell lymphoma.
Lead Product(s): MEN1703
Therapeutic Area: Oncology Product Name: MEN1703
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Ryvu Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Under the agreement, Menarini will develop, manufacture and commercialise orally administered Janus kinase (JAK) inhibitor Smyraf Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis.
Lead Product(s): Peficitinib Hydrobromide
Therapeutic Area: Immunology Product Name: Smyraf
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Astellas Pharma
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 12, 2023
Details:
ELZONRIS® (tagraxofusp), a recombinant protein is the only approved treatment for patients with blastic plasmacytoid dendritic cell neoplasm, and the first and only approved CD123-targeted therapy, in both the United States and Europe.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Elzonris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nippon Shinyaku
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
